Related Experiment Videos
The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study.
M Leone1, A Attanasio, D Croci
1Istituto Nazionale Neurologico Carlo Besta, Milan, Italy.
Neurology
|July 13, 2000
Summary
m-chlorophenylpiperazine (mCPP) triggered more migraines in both healthy individuals and migraineurs compared to placebo. This suggests specific serotonin receptor subtypes play a role in migraine development.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Migraine is a complex neurological disorder with unclear pathophysiology.
- Serotonergic pathways are implicated in migraine, but specific receptor roles remain debated.
Purpose of the Study:
- To investigate the migraine-inducing potential of m-chlorophenylpiperazine (mCPP).
- To explore the involvement of serotonin receptor subtypes in migraine attacks.
Main Methods:
- A double-blind, placebo-controlled study was conducted.
- m-chlorophenylpiperazine (mCPP) was administered at 0.5 mg/kg to 20 healthy controls and 19 migraineurs.
- Migraine incidence was monitored over 24 hours post-administration.
Main Results:
- More migraine attacks occurred after mCPP administration than placebo in both healthy subjects and migraineurs.
- This effect was observed within 24 hours of mCPP administration.
Conclusions:
- The findings support the involvement of serotonin 5-HT2B, 5-HT2C, and 5-HT1A receptor subtypes in migraine pathophysiology.
- mCPP may serve as a useful pharmacological tool for studying migraine mechanisms.